December 2025: Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
December 2025: Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial
-
Narrated by:
-
By:
About this listen
Dr. Suresh Durgam (Intra-Cellular Therapies, a Johnson & Johnson Company, Bedminster, NJ) joins AJP Audio to discuss a phase 3 randomized controlled trial looking at the use of the antipsychotic medication lumateperone as adjunctive to antidepressant therapy in the treatment of patients with major depressive disorder. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin discusses the rest of the December issue of the Journal.
- 00:48 Durgam interview
- 03:09 Mechanism of action
- 04:44 Patient-reported outcomes
- 06:31 Immediate clinical implications
- 07:32 Limitations
- 08:08 Further research
- 09:25 Kalin interview
- 09:38 Durgam et al.
- 13:09 Lin et al.
- 17:22 Brodsky et al.
Transcript
Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.
Subscribe to the podcast here.
Listen to other podcasts produced by the American Psychiatric Association.
Browse articles online.
How authors may submit their work.
Follow the journals of APA Publishing on Twitter.
E-mail us at ajp@psych.org